Clinical trial · Observational
The Impact of Radiotherapy on Oligometastatic Cancer
Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastasis | — | UNRESOLVED | — |
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Metastatic Lung Cancer | Malignant Lung Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Prostate Cancer | Malignant Prostate Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| To propose a diagnostic test for Oligometastatic Cancer (OC). | Diagnostic Test | — | UNRESOLVED |
| To propose a diagnostic test to determine the effectiveness of SABR. | Diagnostic Test | — | UNRESOLVED |
| To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR). | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- OC-SABR
- description
- Patients diagnosed with Oligometastatic Cancer (OC) that will receive Stereotactic ABlative Radiotherapy (SABR) that has been prescribed per clinical protocol.
- interventionNames
- Diagnostic Test: To propose a diagnostic test to determine the viability of Stereotactic ABlative Radiotherapy (SABR).
- Diagnostic Test: To propose a diagnostic test to determine the effectiveness of SABR.
- Diagnostic Test: To propose a diagnostic test for Oligometastatic Cancer (OC).
- label
- Controls
- description
- Individuals who have never been diagnosed with cancer or oligometastasis.
- interventionNames
- Diagnostic Test: To propose a diagnostic test for Oligometastatic Cancer (OC).
Primary outcomes (3)
- measure
- Radiological rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic confirmation of primary tumor: breast, prostate, lung, colorectal. * 18 years old or older. * Up to five metastases located in the bone, lung, node, liver or brain. * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1. Exclusion Criteria: * Non-melanoma skin cancer. * Previous radiotherapy in the same anatomic location. * Presence of vascular collagen disease. * Pregnancy or lactation at the time of inclusion.
References
Publications (0)
Data not yet available